DDInter528 DDInter927
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Disopyramide
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Levacetylmethadol
Dextropropoxyphene {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dextropropoxyphene {u} (Compound) upregulates {v} (Gene) UBQLN2
Dextropropoxyphene {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Dextropropoxyphene {u} (Compound) downregulates {v} (Gene) RUVBL1
Dextropropoxyphene {u} (Compound) causes {v} (Side Effect) Asthenia
Dextropropoxyphene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Dextropropoxyphene (Compound) resembles Disopyramide (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Dextropropoxyphene (Compound) binds CYP3A7-CYP3A51P (Gene)
Dextropropoxyphene (Compound) upregulates UBQLN2 (Gene)
Dextropropoxyphene (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Dextropropoxyphene (Compound) downregulates RUVBL1 (Gene)
Dextropropoxyphene (Compound) causes Asthenia (Side Effect)
Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole